Although the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy recommends triple therapy involving long-acting muscarinic antagonists (LAMAs), long-acting β 2 -agonists (LABAs) and inhaled corticosteroids (ICS) only for further advanced patients, particularly for those at a high risk for exacerbation (GOLD D), triple therapy is widely prescribed in real-life management of chronic obstructive pulmonary disease (COPD), even in patients with mild or moderate COPD severity, likely because physicians prefer to prescribe a full treatment to ensure the best care to their patients. While the available clinical evidence on triple therapy has greatly increased in recent years, there is still no solid evidence to indicate whether and when addition of an ICS to the LABA/LAMA combination provides additional clinical value. Therefore, a strong recommendation can still not be generated but the results of four recent pivotal triple therapy studies support the possibility that this treatment option should be considered also for GOLD B patients. (BRN Rev. 2018;4(4):287-303)
IntroductIon
The Global Initiative for Obstructive Lung Disease (GOLD) strategy recommends treating patients at lower risk of exacerbations (group B) with a long-acting bronchodilator, escalating to dual bronchodilation if symptoms persist, but dual bronchodilation is the first-choice initial treatment for patients of GOLD D, i.e. patients with COPD assessment test (CAT) ≥ 10 units plus ≥ 2 moderate exacerbations and/or ≥ 1 severe exacerbation in the previous year 1 . Actually, all long-acting muscarinic receptor antagonist (LAMA)/long-acting β 2 -agonist (LABA) combinations are always more effective than the LAMA or LABA alone in terms of improvement in trough forced expiratory volume in one second (FEV 1 ), Transition Dyspnoea Index (TDI) and St. George's Respiratory Questionnaire (SGRQ) scores 2 . There is also some evidence that LAMA/LABA combinations result in fewer acute exacerbations of COPD (AECOPDs) and pneumonia, and larger improvement in FEV 1 than LABA/inhaled corticosteroid (ICS) combinations 3 .
The GOLD strategy also recommends an escalation to a triple therapy, which adds ICS to dual-bronchodilator therapy or a LAMA to existing LABA/ICS, only after having maximised bronchodilator treatment with LAMA/ LABA regimens and be limited to patients with more symptomatic GOLD D, because there is no conclusive evidence on the superiority of triple therapy over other therapeutic options, particularly in patients at low risk of exacerbations 1 .
Nevertheless, triple therapy is widely prescribed in real-life management of COPD, even in patients with mild or moderate COPD severity, as demonstrated by retrospective observational studies in the United States 4 (US) and United Kingdom (UK) 5, 6 .
Several independent factors, such as being older, having undergone pulmonary or spirometry evaluation or having been placed on LABA/ ICS fixed-dose combination (FDC) therapy at diagnosis, the presence of comorbid asthma and the possibility of a better control of symptoms can predict prescriptions of triple therapy in clinical practice regardless of the severity of airflow limitation 7, 8 . However, there is also real-world evidence that patients with COPD are more likely to initiate open-triple therapy following initiation with LAMA monotherapy, compared with LABA/ICS therapy 9 . It has been speculated that, at least in Sweden, the widespread use of triple therapy is due to the chronic characteristics of the disease, with a documented high proportion of persistent breathlessness in spite of maximum optimised treatment 10 . Other potential explanations may be increased availability of inhaled therapy in different devices and combinations, overtreatment due to heavy marketing from pharmaceutical companies, and increased awareness and implementation of GOLD ABCD recommendations.
In any case, the use of triple therapy is not only a practice of general practitioners; also pulmonologists often prefer to use triple therapy, even in patients who are not suffering from severe COPD 11 . The Adelphi Respiratory Disease Specific Programme documented that considerable proportions of patients in the low risk groups (GOLD A and B) were currently receiving LABA/ICS, either alone or in combination with a LAMA 12 . Actually, the percentage of 3813 patients with COPD recruited in the survey by an equal number of primary care physicians and pulmonologists working in the US and five European countries (France, Germany, Italy, Spain and the UK) who were receiving LABA/ICS + LAMA or LABA + ICS + LAMA, was 11.8% in patients with GOLD A and 23.8% in those with GOLD B. This prescriptive behaviour is likely due to the confidence that physicians have in starting a full treatment to ensure the best care to their patients 13 .
trIPle therAPy AdmInIstered usIng multIPle InhAlers
The confidence of physicians that triple therapy provides the best care to their patients should be based on personal clinical experience but, above all, on scientific evidence. Meta-analyses of published data (Table 1) or observational studies are useful to help in understanding the real role of triple therapy in COPD.
In 2011, a Cochrane review 14 was able to examine only three studies, two lasting three months and the third one year 17 . Heterogeneity and wide confidence intervals did not draw any conclusions from the outcomes except for an improvement in the health-related quality of life (HRQoL) scores and lung function for triple therapy versus tiotropium alone. However, the Canadian Optimal Therapy of COPD (OPTIMAL) study showed that the free LAMA + LABA/ICS combination, compared with LAMA alone or LABA/ICS, caused the greatest reduction in hospitalisations due to AECOPD 17 .
A second Cochrane review published in 2016 18 added other three studies, one lasting three months 19 and the other two six months 20, 21 . This review showed an evidence of moderate quality that combining tiotropium + LABA/ICS compared with tiotropium monotherapy was able to decrease hospital admission. Lung function was slightly, but significantly, better in the combined therapy group, but the improvement in HRQoL with combined therapy was of low-quality evidence. Evidence was also insufficient to support the benefit of tiotropium + LABA/ICS for mortality and exacerbations (moderate-and low-quality evidence, respectively).
The Italian observational study Long-term outcomes and adverse events of therapy with inhaled corticosteroids, long-acting β 2 -agonists and anticholinergic drugs in hospitalised patients with COPD (OUTPUL) documented that tiotropium + LABA/ICS did not reduce AECOPDs within a one-year follow-up period compared with LABA/ICS alone among patients discharged after a COPD exacerbation, although it was more effective in preventing moderate exacerbations compared to LABA/ICS in frequent exacerbators 22 . Also a retrospective cohort study using a National Health Service (NHS) database of UK patients with COPD supported the signal indicating that tiotropium + LABA/ICS may confer benefits in reducing all-cause mortality, exacerbations requiring oral glucocorticoids (-29%), and hospital admissions (-15%) compared with LABA/ICS 23 .
The only information derived from the Cochrane reviews and pooled analysis of the UK primary data was the possible advantage of adding tiotropium in patients on regular treatment with LABA/ICS. However, a post hoc analysis of pooled data from four 12-week
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Collaborative research 290 BRN Rev. 2018;4(4) 25 , a post hoc analysis from the GLycopyrronium bromide in COPD airWays clinical study 6 (GLOW6) study showed that over 12 weeks, the free triple combination with glycopyrronium bromide (GB) + IND + ICS induced significantly better improvements in lung function and dyspnoea compared to the free double combination (IND + ICS) in symptomatic patients with moderate-to-severe COPD 26 .
This is interesting information for the treatment of patients with COPD, to whom we must guarantee mainly appropriate administration of the bronchodilators, with a more controversial role for ICS. For this reason, as rightly pointed out by Lopez-Campos et al. 27 , due to the lack of specific clinical trials, it seems more reasonable to use the combination of LAMA/LABA + ICS in COPD than to add a LAMA to LABA/ICS. Actually, a Scottish real-life retrospective analysis showed that in patients exposed to ICS, concomitant use of LAMA alone as dual therapy or in combination with LABA as triple therapy was associated with reductions in all-cause mortality, while concomitant use of LABA without LAMA conferred no reduction 28 . Moreover, only triple therapy was found to confer benefits on cardiovascular mortality. On the other side, in the Withdrawal of inhaled glucocorticoids and exacerbations of COPD (WISDOM) study, although the withdrawal of ICS induced a trend toward an increased risk for severe exacerbations, this did not reach significant levels 29 .
In 2015, a systematic review and a meta-analysis that compared triple therapy versus dual bronchodilator therapy 30 could include only two studies: the OPTIMAL trial 17 , and the WISDOM study 29 . There was no difference in all-cause mortality, all-cause admission, exacerbation, adverse effect, and serious adverse effect between the dual-bronchodilator and the triple therapy arms. The triple therapy was slightly associated with favourable impacts on both the FEV 1 and the SGRQ total score in both studies, although the observed difference did not reach the minimum clinically important difference (MCID) in either (i.e. 50 mL for FEV 1 and four points for the total SGRQ score).
PhArmAcologIcAl rAtIonAle for trIPle InhAled therAPy
The favourable pharmacological interaction between inhaled β 2 -agonists and corticosteroids
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Collaborative research 292 BRN Rev. 2018; 4(4) in COPD is a concept that has been developed for a long time 31 . We documented that combining beclometasone dipropionate (BDP) with formoterol furoate (FF) at 100:6 concentration-ratio not only improved the effectiveness of FF, but also elicited a synergistic bronchorelaxant effect in both medium and small airways 32 . Multiple mechanisms could account for the clinical efficacy of LABA/ICS combination therapies 33 . In particular, glucocorticoids increase the numbers of β 2 -adrenoceptors and β 2 -agonists induce direct bronchodilation, and act on glucocorticoid receptors to increase the anti-inflammatory effects of glucocorticoids 33 . The exact effect of LABAs on ICS is uncertain, but a synergistic interaction may likely exist 31 . While the molecular basis of synergy remains unclear, it is probable that mechanistic interpretations must accommodate gene-specific regulation 34 .
In any case, we strongly believe that mechanisms affecting airway obstruction, inflammation, structural changes, and mucociliary dysfunction could all together account for the clinical efficacy of LABA/ICS combination therapies 31 .
Our group has repeatedly described the strong pharmacological rationale that supports the use of double bronchodilation 35, 36 , and has also widely documented with translational studies that the combination of a LABA with a LAMA leads to a synergistic release of the airway smooth muscle (ASM) 37, 38 .
We have also demonstrated that the acute administration of BDP and GB induces a significant relaxation of passively sensitised ASM pre-contracted with histamine, by causing submaximal/maximal inhibition of the contractile tone in both medium bronchi and bronchioles 39 . However, the LAMA/ICS combination synergistically enhanced only the relaxation of passively sensitised medium and small bronchi. These pre-clinical findings may suggest that there is no advantage in combining a LAMA and an ICS in COPD patients.
The evidence of a true pharmacological advantage deriving from the combination of LAMA + LABA + ICS is still absent, but it could be supposed that the possible synergism of action with the LABA + ICS might be added to the well-documented synergistic effect of the LAMA + LABA combinations. Unfortunately, so far there is no study evaluating the in vitro pharmacological interactions of triple therapy.
trIPle therAPIes under develoPment
Although the reviewed evidence is not solid enough to support the regular use of triple therapy in COPD, it is likely that the usual prescriptive behaviour of physicians that favours the triple therapy even in those patients with COPD whose airflow limitation is not severe is the main reason why the pharmaceutical industry has interest in developing LAMA/LABA/ICS FDC.
Triohale (tiotropium 18 μg + FF 12 μg + ciclesonide 400 μg) was the first triple combination to enter the market, at least in India. A 24-week, open-label, prospective, non-comparative, multicentre, real-world study, which enrolled patients with COPD requiring triple therapy as assessed by physician, documented that lung function and symptoms significantly BARCELONA RESPIRATORY NETWORK improved in patients with COPD, independent of their smoking history 40 .
There is much more information on three other triple combinations that are still under development. Detailed pharmacological characteristics of LAMAs, LABAs and ICS included in these FDCs are reported in table 2. In the TRINITY study, GB/FF/BDP was compared with FF/BDP + tiotropium (open triple) and with tiotropium alone in a 52-week study 43 . The inclusion criteria were very similar to those of TRILOGY. Triple therapy improved pre-dose FEV 1 (+61 mL) compared with tiotropium, but there was no difference between fixed and ex-temporary triple combination (-3 mL). The adjusted annual rate of moderate-to-severe exacerbations was 0.46 for GB/FF/BDP and 0.57 for tiotropium, with a rate ratio of 0.80, indicating a 20% reduction with GB/FF/BDP. No difference was observed between fixed and ex-temporary triple combination either in adjusted annual rate of moderate-to-severe exacerbations (0.46 versus 0.45). A large RCT has evaluated the non-inferiority of single-inhaler UMEC/VI/FLF versus VI/FLF + UMEC using two inhalers and has shown that single-inhaler triple therapy with UMEC/ VI/FLF offers similar efficacy, HRQoL, and safety benefits as the same triple therapy administered using two inhalers 49 .
The Informing the Pathway of COPD Treatment (IMPACT) trial has been a Phase III, randomised, double-blind, three-arm, parallel-group, global multicentre study comparing the rate of moderate and severe exacerbations between UMEC/VI/FLF and VI/FLF or UMEC/ VI in 10,355 patients with COPD over a 52-week treatment period 50 . Patients had to have either a FEV 1 less than 50% of the predicted normal value and a history of at least one moderate or severe exacerbation in the previous year, or an FEV 1 of 50 to 80% of the predicted normal value and at least two moderate exacerbations or one severe exacerbation in the previous year.
There was a significant reduction in moderate-to-severe exacerbation rate with triple therapy (-15% versus VI/FLF and -25% versus UMEC/VI). Umeclidinium/vilanterol/fluticasone furoate was more effective than the other two treatments in improving the trough FEV 1 at week 52 (+97 mL versus VI/FF, and +54 mL versus UMEC/VI). It was also significantly better than the other two treatments with respect to the impact on SGRQ total score and in the percentage of patients who had a response as defined by a decrease in the SGRQ total score of at least 4 points. Furthermore, in a subset of 5058 patients, the percentage of patients who had a response as defined by an increase in the TDI of at least one unit was higher with triple therapy than with either dual therapy. 53 . The latter study is a randomised, double-blind, parallel-group, 24-week, chronic-dosing, multi-centre trial to assess the efficacy and safety of GB/FF/BUD FDC. The trial compared GB/FF/BUD FDC to GB/FF 14.4/9.6 µg using ADT, FF/BUD 12/400 μg Turbuhaler and FF/BUD 9.6/320 µg using ADT. Triple combination demonstrated a statistically significant improvement compared with dual combination therapies in six out of seven lung function primary endpoints based on FEV 1 assessments in patients with moderate-to-very-severe COPD. In total, eight of the nine primary endpoints in the KRONOS trial were met, including two non-inferiority endpoints to qualify FF/BUD 9.6/320 µg delivered using ADT. 
WhAt does neW evIdence tell us?
Nowadays, we have evidence that LAMA/ LABA FDCs may be more effective than LABA/ ICS in reducing the risk of exacerbations 54 and this finding raises the fundamental question of whether the potential benefit gained by adding ICS to the dual-bronchodilator therapy actually overcomes the risk of adverse effects and the increased cost of triple therapy 30 .
The TRIBUTE study demonstrated a 15% reduction in exacerbations with triple therapy compared with dual bronchodilation 44 . However, TRIBUTE, as well as TRILOGY 42 and TRINITY 43 studies, was not focused on frequent exacerbators and, consequently, the annual rate of exacerbations was too low to evaluate the true value of this reduction. Therefore, it is difficult to draw firm conclusions on this finding. Likely, it would be preferable to calculate how many exacerbations requiring medical intervention would be prevented for every 100 patients treated for one year with GB/FF/BDP versus GB/IND therapy. In any case, the rates of moderate and severe exacerbations analysed separately were not significantly different between GB/FF/BDP and GB/IND. Also the time to first moderate or severe exacerbation was similar between the two treatment groups. All these findings suggest that either the triple therapy is actually not more effective than double bronchodilation in reducing the risk of exacerbations, or/and the study has been not sufficiently well designed. Also the results of the FULFIL study are not very useful because it was a 24-week trial, but, due to seasonal variation, an evaluation of exacerbation frequency requires a period of ≥ 1 year and, furthermore, the timing of the study treatment may prove important (e.g. capturing winter cold season in the majority of patients) 55 .
The 2018 GOLD strategy suggests for patients with GOLD D escalation from dual bronchodilation to LAMA/LABA/ICS, and when LABA/ ICS therapy does not positively impact exacerbations/symptoms, a LAMA can be added 1 . Regrettably, there is still no solid evidence of a real clinical advantage when performing such an escalation. Suissa and Drazen 56 , while editorialising the IMPACT study data, highlighted that although this trial has addressed the possibility of a step-up approach from a dual long-acting bronchodilator regimen to triple therapy, the results of the study were probably artificially inflated because the majority of the enrolled patients were already treated with ICSs and some of them had a history of asthma. For this reason, they think that the IMPACT trial falls short of providing the anticipated strong evidence to better understand the potential for stepping-up to single inhaler triple therapy in clinical practice. Umeclidinium/vilanterol/fluticasone furoate
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Collaborative research 300 BRN Rev. 2018;4 (4) and VI/FLF also showed a signal toward lower all-cause mortality during treatment than UMEC/VI 50 . However, we do not believe that it is an outcome endowed with consistency, and not only because it contradicts the results of the Study to Understand Mortality and Morbidity in COPD (SUMMIT) study that was powered to evaluate all-cause mortality and did not show a significant effect for VI/FLF 57 , but also, and mainly because death from any cause during treatment was not a pre-specified primary and secondary outcome. This means that the study was not appropriately powered to assess effects on mortality.
At this point in time, we are waiting for the results of the ETHOS study, mainly because of the number of patients involved. However, we must highlight that the step-up approach from dual bronchodilation to triple therapy takes no account of the critical differences in COPD exacerbations (they differ in aetiology, severity, and biological substrate), and thus it is not designed on the patient's specific needs to be treated 58 .
In any case, we fully agree that the available evidence does support the current recommendation of triple therapy for GOLD D patients, but it only suggests triple therapy is effective in GOLD B patients (i.e. highly symptomatic but at low risk of exacerbations) 59 . Therefore, the current GOLD strategy recommendations should be revisited and studies with triple therapy in GOLD B patients should be conducted with the aim of testing its effect on hospitalisations and survival 59 . However, Suissa and Drazen 56 have invoked caution in using the single-inhaler triple therapy in treating COPD because any potential benefit could be lost and potential undue harm induced if triple therapy is expanded to GOLD A, B, and C patients. Now we must establish whether and when addition of an ICS to the LAMA/LABA combination provides real additional clinical value, regardless of a preventive effect on exacerbations, and determine what kind of benefit it is, or whether LAMA/LABA combination therapy is preferred over triple therapy also because of the cost differences of the two treatments in real-life. It has been suggested that baseline blood eosinophil levels may represent an informative marker for exacerbation reduction with LABA/ICS in patients with COPD and a history of moderate-to-severe exacerbations 60 . Nonetheless, prospective analyses of data from the Effect of Indacaterol Glycopyronium versus Fluticasone Salmeterol on COPD Exacerbations (FLAME) trial indicate that dual bronchodilation provides superior or similar benefits over LABA/ICS regardless of blood eosinophil levels in patients with COPD 61 . In the TRIBUTE trial, the relative effect of GB/FF/ BDP versus GB/IND on moderate-to-severe exacerbations was greater in patients with eosinophils > 2%, but the effect of the two treatments was not significantly different when an eosinophil threshold of 200 cells per μL was used 44 . However, in the IMPACT study, the annual rate of moderate-to-severe exacerbations was lower with triple therapy regardless of eosinophil level 50 . Therefore, it is obvious that at the present time blood eosinophil counts cannot be recommended as an unquestionable biomarker for the management of individual patients with COPD 62 .
In any case, we agree that it can be difficult to discern whether an individual who continues to experience exacerbations following the
addition of an ICS would have experienced a similar number or more of these events without this addition 63 .
Also the evaluation of possible risk of adverse events is central to the choice of therapy. The overall incidence of pneumonia in the IMPACT study was 50% higher in patients treated with UMEC/VI/FLF than in the UMEC/VI group 50 , whereas in the TRIBUTE trial the addition of BDP did not increase the risk of pneumonia 44 .
conclusIons
Although the available information has greatly increased in recent years, there is still no solid evidence to state whether and when addition of an ICS to the LAMA/LABA combination provides additional clinical value. Therefore, a strong recommendation cannot be generated as yet. However, it is likely that the fundamental question in the next paradigm for the treatment of COPD will no longer be whether and/or when it is appropriate to switch patients with COPD from a LABA/ICS regimen to a LAMA/LABA one, but rather in which patients and when we can add an ICS to the dual bronchodilation.
We strongly believe that maximising the treatment in patients with a degree of clinical instability by including an ICS in the therapeutic regimen is useful to control the disease but may not be needed during periods of clinical stability. However, it is always better to avoid a therapeutic step-up progression when it is not needed rather than being forced subsequently into a step-down approach in which the outcome is always unpredictable 64 . 
